Pathogenic role of IL-17 in psoriasis and psoriatic arthritis

Chiricozzi, A.

doi:10.1016/S0001-7310(14)70014-6

array:22 ["pii" => "S0001731014700146" "issn" => "00017310" "doi" => "10.1016/S0001-7310(14)70014-6" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "70014" "copyright" => "Academia Española de Dermatología y Venereología" "copyrightAnyo" => "2014" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:9-20" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1123 "formatos" => array:3 [ "EPUB" => 36 "HTML" => 327 "PDF" => 760 ] ] "itemSiguiente" => array:17 [ "pii" => "S0001731014700158" "issn" => "00017310" "doi" => "10.1016/S0001-7310(14)70015-8" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "70015" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:21-33" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 770 "formatos" => array:3 [ "EPUB" => 32 "HTML" => 273 "PDF" => 465 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "21" "paginaFinal" => "33" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "IL-17 e IL-17R: una diana terapéutica favorable para la enfermedad psoriásica" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Mitra, S.K. Raychaudhuri, S.P. Raychaudhuri" "autores" => array:3 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Mitra" ] 1 => array:2 [ "nombre" => "S.K." "apellidos" => "Raychaudhuri" ] 2 => array:2 [ "nombre" => "S.P." "apellidos" => "Raychaudhuri" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731014700158?idApp=UINPBA000044" "url" => "/00017310/00000105000000S1/v1_201411120051/S0001731014700158/v1_201411120051/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S0001731014700134" "issn" => "00017310" "doi" => "10.1016/S0001-7310(14)70013-4" "estado" => "S300" "fechaPublicacion" => "2014-10-01" "aid" => "70013" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "simple-article" "subdocumento" => "edi" "cita" => "Actas Dermosifiliogr. 2014;105 Supl 1:6-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 460 "formatos" => array:3 [ "EPUB" => 28 "HTML" => 245 "PDF" => 187 ] ] "en" => array:7 [ "idiomaDefecto" => true "titulo" => "IL-17 in psoriasis. The final frontier or just another brick in the wall?" "tienePdf" => "en" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "6" "paginaFinal" => "8" ] ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.M. Carrascosa, L. Puig" "autores" => array:2 [ 0 => array:2 [ "nombre" => "J.M." "apellidos" => "Carrascosa" ] 1 => array:2 [ "nombre" => "L." "apellidos" => "Puig" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731014700134?idApp=UINPBA000044" "url" => "/00017310/00000105000000S1/v1_201411120051/S0001731014700134/v1_201411120051/en/main.assets" ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Pathogenic role of IL-17 in psoriasis and psoriatic arthritis" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "9" "paginaFinal" => "20" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "A. Chiricozzi" "autores" => array:1 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Chiricozzi" ] ] "afiliaciones" => array:2 [ 0 => array:2 [ "entidad" => "Department of Dermatology, University of Rome Tor Vergata, Rome, Italy" "identificador" => "aff0005" ] 1 => array:2 [ "entidad" => "Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA" "identificador" => "aff0010" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Papel patógeno de la IL-17 en la psoriasis y en la artritis psoriásica" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec360878" "palabras" => array:8 [ 0 => "IL-17" 1 => "Psoriasis" 2 => "Arthritis" 3 => "Secukinumab" 4 => "Ixekizumab" 5 => "Brodalumab" 6 => "Atherosclerosis" 7 => "Obesity" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec360879" "palabras" => array:8 [ 0 => "IL-17" 1 => "Psoriasis" 2 => "Artritis" 3 => "Secukinumab" 4 => "Ixekizumab" 5 => "Brodalumab" 6 => "Aterosclerosis" 7 => "Obesidad" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics.Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "La psoriasis es un trastorno crónico inflamatorio de la piel resultante de un complejo sistema de citocinas y quimiocinas producidas por varios tipos de células inmunes y células tisulares. La evidencia incipiente sugiere un papel central de la IL-17 y el eje IL-23/T17 en la patogénesis de la psoriasis, lo que ofrece una base para el uso de agentes bloqueadores de la IL-17 como tratamiento.Están siendo estudiados en estudios clínicos en fase III tres agentes enfocados en la señalización de la IL-17: secukinumab e ixekizumab (agentes neutralizantes de la IL-17), y brodalumab (antagonista del receptor de la IL-17). Los resultados preliminares son altamente prometedores para todos los agentes anti-IL17, lo que crea claras expectativas para esta clase de agentes como un nuevo planteamiento terapéutico eficaz para el tratamiento de la psoriasis." ] ] ] "idiomaDefecto" => "en" "url" => "/00017310/00000105000000S1/v1_201411120051/S0001731014700146/v1_201411120051/en/main.assets" "Apartado" => array:4 [ "identificador" => "6148" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/00017310/00000105000000S1/v1_201411120051/S0001731014700146/v1_201411120051/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731014700146?idApp=UINPBA000044"]

Actas Dermo-Sifiliográficas

ISSN: 0001-7310

The Official publication of the Spanish Academy of Dermatology and Venereology (AEDV). Actas Dermo-Sifiliográficas, founded in 1909, is the oldest monthly medical journals published in Spain. In the year 2006 has been indexed in the Medlinedatabase, and has become a vehicle for expressing the most current Spanish medicine and modern. All articles are subjected to a rigorous process of revision in pairs, and careful editing for literary and scientific style. Together with the classic Original and Clinical Case Study sections, we also include Reviews, Case Diagnoses, and Book Reviews. Dermo-Sifiliográficas is an essential publication for anyone who needs to be current on all aspects of Spanish and world dermatology.

Con su JCI 2023, Actas Dermo-Sifiliográficas es Q1 y se posiciona la revista nº 15 de 94 en Dermatología

With JCI 2023, Actas Dermo-Sifiliográficas is Q1 and is ranked number 15 of 94 in Dermatology

Indexed in:

Web of Science, Emerging Sources Citation Index (WoS, Clarivate), PubMed/Medlinee, IME, Embase/Excerpta Medica, Embase, Toxline, Cab Abstracts, Cab Health, Cancerlit NIm, Serline: Biomed, Bibliomed, Pascal, Scopus , IBECS

Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics.

Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.

Keywords:

IL-17

Psoriasis

Arthritis

Secukinumab

Ixekizumab

Brodalumab

Atherosclerosis

Obesity

Resumen

La psoriasis es un trastorno crónico inflamatorio de la piel resultante de un complejo sistema de citocinas y quimiocinas producidas por varios tipos de células inmunes y células tisulares. La evidencia incipiente sugiere un papel central de la IL-17 y el eje IL-23/T17 en la patogénesis de la psoriasis, lo que ofrece una base para el uso de agentes bloqueadores de la IL-17 como tratamiento.

Están siendo estudiados en estudios clínicos en fase III tres agentes enfocados en la señalización de la IL-17: secukinumab e ixekizumab (agentes neutralizantes de la IL-17), y brodalumab (antagonista del receptor de la IL-17). Los resultados preliminares son altamente prometedores para todos los agentes anti-IL17, lo que crea claras expectativas para esta clase de agentes como un nuevo planteamiento terapéutico eficaz para el tratamiento de la psoriasis.

Palabras clave:

IL-17

Psoriasis

Artritis

Secukinumab

Ixekizumab

Brodalumab

Aterosclerosis

Obesidad

Full text is only aviable in PDF

Tools

Indexed in:

Follow us:

Subscribe to our newsletter